Peer Review History
| Original SubmissionJanuary 11, 2020 |
|---|
|
PONE-D-20-00967 Trends and forecasts of leprosy for a hyperendemic city from Brazil’s northeast: Evidence from an eleven-year time-series analysis PLOS ONE Dear Mr Ramos, Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. ============================== Please respond to all reviewer feedback. ============================== We would appreciate receiving your revised manuscript by Apr 27 2020 11:59PM. When you are ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols Please include the following items when submitting your revised manuscript:
Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out. We look forward to receiving your revised manuscript. Kind regards, Eyal Oren, Ph.D. Academic Editor PLOS ONE Journal Requirements: When submitting your revision, we need you to address these additional requirements: 1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at http://www.plosone.org/attachments/PLOSOne_formatting_sample_main_body.pdf and http://www.plosone.org/attachments/PLOSOne_formatting_sample_title_authors_affiliations.pdf 2. We suggest you thoroughly copyedit your manuscript for language usage, spelling, and grammar. If you do not know anyone who can help you do this, you may wish to consider employing a professional scientific editing service. Whilst you may use any professional scientific editing service of your choice, PLOS has partnered with both American Journal Experts (AJE) and Editage to provide discounted services to PLOS authors. Both organizations have experience helping authors meet PLOS guidelines and can provide language editing, translation, manuscript formatting, and figure formatting to ensure your manuscript meets our submission guidelines. To take advantage of our partnership with AJE, visit the AJE website (http://learn.aje.com/plos/) for a 15% discount off AJE services. To take advantage of our partnership with Editage, visit the Editage website (www.editage.com) and enter referral code PLOSEDIT for a 15% discount off Editage services. If the PLOS editorial team finds any language issues in text that either AJE or Editage has edited, the service provider will re-edit the text for free. Upon resubmission, please provide the following:
3. We note that you have indicated that data from this study are available upon request. PLOS only allows data to be available upon request if there are legal or ethical restrictions on sharing data publicly. For information on unacceptable data access restrictions, please see http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions. In your revised cover letter, please address the following prompts: a) If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially identifying or sensitive patient information) and who has imposed them (e.g., an ethics committee). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent. b) If there are no restrictions, please upload the minimal anonymized data set necessary to replicate your study findings as either Supporting Information files or to a stable, public repository and provide us with the relevant URLs, DOIs, or accession numbers. Please see http://www.bmj.com/content/340/bmj.c181.long for guidelines on how to de-identify and prepare clinical data for publication. For a list of acceptable repositories, please see http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories. We will update your Data Availability statement on your behalf to reflect the information you provide. 4. We note that Figure 1 in your submission contains map images which may be copyrighted. All PLOS content is published under the Creative Commons Attribution License (CC BY 4.0), which means that the manuscript, images, and Supporting Information files will be freely available online, and any third party is permitted to access, download, copy, distribute, and use these materials in any way, even commercially, with proper attribution. For these reasons, we cannot publish previously copyrighted maps or satellite images created using proprietary data, such as Google software (Google Maps, Street View, and Earth). For more information, see our copyright guidelines: http://journals.plos.org/plosone/s/licenses-and-copyright. We require you to either (1) present written permission from the copyright holder to publish these figures specifically under the CC BY 4.0 license, or (2) remove the figures from your submission: 1. You may seek permission from the original copyright holder of Figure 1 to publish the content specifically under the CC BY 4.0 license. We recommend that you contact the original copyright holder with the Content Permission Form (http://journals.plos.org/plosone/s/file?id=7c09/content-permission-form.pdf) and the following text: “I request permission for the open-access journal PLOS ONE to publish XXX under the Creative Commons Attribution License (CCAL) CC BY 4.0 (http://creativecommons.org/licenses/by/4.0/). Please be aware that this license allows unrestricted use and distribution, even commercially, by third parties. Please reply and provide explicit written permission to publish XXX under a CC BY license and complete the attached form.” Please upload the completed Content Permission Form or other proof of granted permissions as an "Other" file with your submission. In the figure caption of the copyrighted figure, please include the following text: “Reprinted from [ref] under a CC BY license, with permission from [name of publisher], original copyright [original copyright year].” 2. If you are unable to obtain permission from the original copyright holder to publish these figures under the CC BY 4.0 license or if the copyright holder’s requirements are incompatible with the CC BY 4.0 license, please either i) remove the figure or ii) supply a replacement figure that complies with the CC BY 4.0 license. Please check copyright information on all replacement figures and update the figure caption with source information. If applicable, please specify in the figure caption text when a figure is similar but not identical to the original image and is therefore for illustrative purposes only. The following resources for replacing copyrighted map figures may be helpful: USGS National Map Viewer (public domain): http://viewer.nationalmap.gov/viewer/ The Gateway to Astronaut Photography of Earth (public domain): http://eol.jsc.nasa.gov/sseop/clickmap/ Maps at the CIA (public domain): https://www.cia.gov/library/publications/the-world-factbook/index.html and https://www.cia.gov/library/publications/cia-maps-publications/index.html NASA Earth Observatory (public domain): http://earthobservatory.nasa.gov/ Landsat: http://landsat.visibleearth.nasa.gov/ USGS EROS (Earth Resources Observatory and Science (EROS) Center) (public domain): http://eros.usgs.gov/# Natural Earth (public domain): http://www.naturalearthdata.com/ [Note: HTML markup is below. Please do not edit.] Reviewers' comments: Reviewer's Responses to Questions Comments to the Author 1. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. Reviewer #1: Yes Reviewer #2: Yes ********** 2. Has the statistical analysis been performed appropriately and rigorously? Reviewer #1: Yes Reviewer #2: Yes ********** 3. Have the authors made all data underlying the findings in their manuscript fully available? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified. Reviewer #1: Yes Reviewer #2: No ********** 4. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here. Reviewer #1: Yes Reviewer #2: Yes ********** 5. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters) Reviewer #1: 1. Summary of the research In your own words, summarize the main research question, claims, and conclusions of the study. Provide context for how this research fits within the existing literature. Discuss the manuscript’s strengths and weaknesses and your overall recommendation. The objective of this research was to estimate the temporal trends of leprosy according to sex and age groups, and to estimate and predict the progression of leprosy in Imperatriz, Maranhão, Brazil, a hyperendemic city in the northeast of Brazil. Through the authors’ research, they found that while new case detection rates are declining in total, that data stratified by age and sex shows a different trajectory in certain groups. Namely that case detection rates among those less than 15 years of age and among women over 60 show an increase. Additionally the data show that those in the age range of 30 to 59 are the largest proportion of those affected by leprosy, even with the downward trend in case detection. The discussion of results and conclusions are sound and recommend continued active surveillance to reduce leprosy transmission in highly endemic regions, even though overall new case detection is declining in the country. Additionally, discussion of social issues of men and women in relation to accessing health services and stigma is well documented in the manuscript and cites literature to support the recommendations. The discussion of the final models for leprosy case detection show a decrease in total and among men and women separately. While I am not familiar with the epidemiology in predictive modeling utilized, the results are well described and match the findings. Authors discuss limitations of using a secondary dataset. All ethics considerations have been addressed sufficiently. Overall I found this manuscript to be very comprehensive. The research is important, which the authors state, because new case incidence rates are remaining stable or are not declining at the rate seen in the rest of the country, indicating continued active transmission. Additionally the prediction is that high case detection rates will continue to be a burden on the population in this hyperendemic area of Brazil. The study meets the criteria for publishing and I recommend publishing after minor edits. 2. Examples and evidence Major issues Major issues must be addressed in order for the manuscript to proceed. Focus on what is essential for the current study, not the next step in the research. Put these items in a list and be as specific as possible. Minor issues Mention additional things the authors should do to improve the manuscript. Typically these will be changes that would not affect the overall conclusions. I found no major issues to be addressed. A recommendation that might strengthen the paper is to include significant tests for discussion of case detection in men in comparison to women. Since men have a higher case detection, it might be interesting for the reader to know if this is significantly higher than case detection in women. The literature cited provides good examples of why men may have more difficulty in accessing health services. However, the “greater occurrence” of leprosy is related to transmission and not in accessing services. This may be a factor in delayed diagnosis and ongoing transmission as authors clearly state, but it might be interesting to include literature on transmission risk in men. Alternatively, since the data show trends, revising the language to exclude reasons for occurrence in exchange for risks for delayed diagnosis may be more appropriate. In line 395 “The decrease in the rate drop” may be confusing. I would suggest to reword this so that the reader understands that the rate drop is not decreasing at the same rate as the time period prior to the year 2000. In line 454 there is a similar statement that “a rapid and continuous decline was observed, caused mainly by a decrease in the intensive search for cases in many countries”. Is this referring to a stability in the number of cases, indicating maintenance of leprosy during this time period? You may consider rewording. There is a repeated phrase in lines 433 and 435. Recommendations from the authors that delay in diagnosis will increase clinical severity of the disease and impairment and also contributes to on-going transmission shows the need for continued active leprosy surveillance to reach elimination goals locally in hyperendemic areas. After minor edits, I recommend to publish this research. 3. Other points (optional) If applicable, add confidential comments for the editors. Raise any concerns about the manuscript that the editors may need to consider further, such as concerns about ethics. Do not use this section for your overall critique. Also mention whether you might be available to look at a revised version. No other points to address. Reviewer #2: Data from the Brazilian National Leprosy Database usually are available to the public through the Internet. Please comment on which data in your study are not available. Specific comments Abstract Lines 40-41 – please remove the conjunction “while” from line 40 or the conjunction “and” from line 41 Lines 43-44 – Table 1 shows positives AMPC for rates among men aged less than 15 years old and among women over 60 years old, but not among women younger than 15 yo. Introduction Lines 59-60 – please use the term “elimination as a public health problem” and include the term “prevalence” before the criteria “<1 case every 10,000 inhabitants”. This is different from elimination of transmission. Here is a good paragraph in your paper to make this difference clear to the reader. Line 64 – reference 4 is unnecessary once it is pointed at the end of the same paragraph Line 66 – replace the term “degree” by “grade 2” or “visible deformities” Line 69 – use the term “global detection” instead of “total” Line 71 – use the term “total” before “cases reported” Line 73 – the reference 6 show a link related to leprosy in Maranhao, why is it used for these data in the text? (http://tabnet.datasus.gov.br/cgi/dhdat.exe?hanseniase/hantfma17.def ) Lines 59-60 – please provide a reference for the following statement about high rates of the disease among Brazilian regions. Line 77 – please remove the verb “was” Lines 82-84 – we suggest to add that the data on G2D is the “rate per 100,000 inhabitants” to make sure the reader will not misunderstand this information as the percentage of G2D among new cases. Line 91 – reference 8 is unnecessary once it is pointed at the end of the same paragraph Line 96 – we suggest to include “the disease” before the verb presents Lines 97-98 – Please provide a reference to the statement: “that is, men are more frequently affected than women in most regions of the world (including Brazil)” Line 104 – Please clarify where Souza’s study was carried out. Line 119 – The period (2006-2016) should not be part of the figure title, unless the municipality area has changed Lines 126-130 – please specify the year for the count or estimation of that population and for main social indicators Lines 142-143 – Please rephrase the following: “The variables adopted in this study include date when leprosy was reported, age and sex” once “age and sex” are unchangeable individual characteristics differently from “date” and clarify if you considered the date of diagnosis or the date when the case was reported to the system. Lines 153-155 – Please specify how total and specific intercensal population was calculated. Results Lines 223-231 – Table 1 shows a continuous increase for new cases detection rates along lifetime, an interesting data not cited by authors. We suggest that table 1 shows the total number of cases, and its related rates and AMPC. Lines 242-243 – The NCDR decreasing trend looks different between the first and second 5 years period, showing a stable tendency especially from 2013 to 2016 which may be further investigated and discussed. Lines 249-254 – we suggest to say that figure 3 shows a decreasing trend for all age-groups and sex, except for men younger than 15 and for women older than 59 yo, which reflects specific AMPC by age and sex. For women younger than 15 and aged 15 to 29 yo there was a slight increase in the last year. This is different from saying that there is an “increasing tendency” for women younger than 15 yo. The same slight increase in 2016 was registered for women aged 15-29 yo but was not mentioned by authors. It is important to observe that the older group is not “over 60” but “aged 60 or more”. Why figure 2 was titled “Leprosy Trend” while figure 3 was titled “Estimated Leprosy Trend”? There is little additional information on figure 4 comparing to figure 3. We suggest excluding this figure. The text from line 265 to 277 may be maintained as comments related to figure 3. Discussion Lines 344-346 – First paragraph just repeat the study’s objective which is unnecessary. Lines 347-353 – Main results of this study was a downward trend of leprosy in the last decade, which will be maintained in the next years accordingly to author’s predictions. Thus, apparently this is not compatible with an “increasing circulation of leprosy bacillus in the region”. Demographic growth and immigration may be linked to the very high rates of leprosy observed in Imperatriz, but the text should be better explained separating that from the apparent decline, which also needs to be discussed. Lines 359-367 – Authors comment only about operational factors possibly related to higher rates of leprosy among men, but other hypotheses as biological aspects are discussed on literature and should be considered. This is pointed by some authors already cited as references for your study. Lines 369 – The study subgroup was not over 60 years old, but over 59. Lines 370-378 – It is important to observe not only that this age group (30-59 yo) presented the highest detection rates, but also to highlight that sharper decreases were registered for them in both sexes (table 1), which may reflects reduction of transmission. Lines 379-385 – As the study was carried out in one municipality only, data from Brazilian population are not adequate to discuss your results. We suggest reporting on Imperatriz population composition and about any changes observed during the study period, like a population aging or decrease on birthrate. Lines 367-389 – An increasing in AMPC is clear for NCDR in female aged 60 or more and for young men, but the same is not so clear for young women, despite a slight late increase in the last year, which cannot be considered as a tendency. This needs to be discussed? What could explain this decreases and increases? MDT? Case search activities for children like school campaign? any specific campaign for the elderly? Do women respond better to those activities? Lines 396-406 – Recent leprosy campaigns for school children in Brazil became globally know, they did not happen in your study area? Would you consider a possible decline in leprosy transmission and not only a decline from operational factors? If this is not a possible hypothesis, please make some comments. Lines 415-418 – Please provide some data from your study that could support the idea of underreporting of cases in children. Did they present a high grade 2 disability rate, for example? Were most of your cases classified as multibacillary despite paucibacillary expected predominance among children? Is the coverage of household contact examination very low? Lines 419-430 – The important progressive increase in NCDRs for elderly females observed in your study from 2011 is really an intriguing result. This was the only rate to reach the same level from the beginning of your time series. Your discussion addressed issues related to a possible later diagnosis for women than men, but you did not present any data from Imperatriz to support this hypothesis, for example, a recent change with increase of grade 2 disability rate for this sex and age group would be an indicator for that. We suggest a deeper investigation on possible specific actions taken for this sex and age group that could have increased leprosy detection from 2011. Lines 437-440 – The text was repeated, please correct it. In your whole study period NCDRs for children younger than 15 yo ranged roughly from 1 to 10 new cases per 100,000 children. On the other hand, you reported that NCDRs for the elderly fluctuated between 10 to 60 new cases per 100,000 people aged 60 or more. Why do you affirm that “individuals younger than 15 years old are more vulnerable to the disease”? Lines 440-442 – You did not report any data about physical disability among the elderly female. Line 446 – please replace “early” by “earlier”. Lines 458-462 – Some published papers registered a real decrease of leprosy in some countries, such as Norway, where there were a decrease of transmission followed by a change in epidemiological pattern of disease towards older ages. This hypothesis should also be considered and discussed by authors in addition to their operational explanations for decreased chances of diagnosis. Lines 473-478 – We suggest a better definition of “elimination of leprosy as a public health problem” and of “elimination of transmission of leprosy”, which can be explained in the introduction of this paper. This will avoid misunderstanding of readers, especially at the end of the discussion section. Line 491 – we suggest reviewing your affirmation that there was a growing trend for women aged less than 15, despite the slight increase in 2016. ********** 6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy. Reviewer #1: No Reviewer #2: No [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files to be viewed.] While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at figures@plos.org. Please note that Supporting Information files do not need this step. |
| Revision 1 |
|
PONE-D-20-00967R1 Trends and forecasts of leprosy for a hyperendemic city from Brazil’s northeast: Evidence from an eleven-year time-series analysis PLOS ONE Dear Dr. Ramos, Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. Please submit your revised manuscript by Jul 17 2020 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. Please include the following items when submitting your revised manuscript:
If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter. If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols We look forward to receiving your revised manuscript. Kind regards, Eyal Oren, Ph.D. Academic Editor PLOS ONE [Note: HTML markup is below. Please do not edit.] Reviewers' comments: Reviewer's Responses to Questions Comments to the Author 1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation. Reviewer #1: (No Response) Reviewer #2: All comments have been addressed ********** 2. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. Reviewer #1: Yes Reviewer #2: Yes ********** 3. Has the statistical analysis been performed appropriately and rigorously? Reviewer #1: Yes Reviewer #2: Yes ********** 4. Have the authors made all data underlying the findings in their manuscript fully available? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified. Reviewer #1: Yes Reviewer #2: Yes ********** 5. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here. Reviewer #1: Yes Reviewer #2: Yes ********** 6. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters) Reviewer #1: (No Response) Reviewer #2: The manuscript reads much better now. I would like to make few additional suggestions: Abstract Line 40 – I suggest using “average incidence” instead of “incidence” only Line 48 – I suggest saying that ‘the city is unlikely to meet a "significant decrease" of the disease burden by 2020’ Introduction Line 75 – I suggest using “In the same year” instead of “In the same period” Materials and methods Line 134 – “In the same period” means 2010? If so, it would be better to use “the same year”. The same should be checked for line 140. Results Line 237 – Revise the use of “both” once you report results for 3 groups, or rephrase it using two categories (for example: “total of cases and cases by sex”) Discussion Line 429 – Replace “by” for “be” Lines 457-461 – Authors have just stated (lines 452-456) that primary health units do not present satisfactory performance in diagnosing leprosy in children because they don’t actively seek cases. Thus it is surprising that Anchieta’s study (2019) observed a decreasing trend in the detection of children under 15 years old because of active case-finding campaigns in the school-aged population. These two statements are not in agreement with each other. Line 477 – We suggest to include “leprosy” before “patients” Line 552 – Please replace “eliminate of transmission” by “eliminate the transmission” ********** 7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy. Reviewer #1: Yes: Christine Murto, PhD Reviewer #2: Yes: Mauricio Lisboa Nobre [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.
|
| Revision 2 |
|
Trends and forecasts of leprosy for a hyperendemic city from Brazil’s northeast: Evidence from an eleven-year time-series analysis PONE-D-20-00967R2 Dear Dr. Ramos, We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements. Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication. An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org. If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org. Kind regards, Eyal Oren, Ph.D. Academic Editor PLOS ONE Additional Editor Comments (optional): Reviewers' comments: Reviewer's Responses to Questions Comments to the Author 1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation. Reviewer #1: All comments have been addressed Reviewer #2: All comments have been addressed ********** 2. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. Reviewer #1: Yes Reviewer #2: Yes ********** 3. Has the statistical analysis been performed appropriately and rigorously? Reviewer #1: Yes Reviewer #2: Yes ********** 4. Have the authors made all data underlying the findings in their manuscript fully available? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified. Reviewer #1: Yes Reviewer #2: Yes ********** 5. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here. Reviewer #1: Yes Reviewer #2: Yes ********** 6. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters) Reviewer #1: Very good and thank you for the revisions to the manuscript. A couple of very small grammatical revisions : Remove "an" Lines 422-430: “Countries that registered a decrease in leprosy transmission, with subsequent elimination, observed a change in the profile of the disease, with a drop in detection in younger age groups and an increase in detection of elderly people [35,42]. In Imperatriz, the high detection rates in the population aged 60 years old or over may be an indicative of a change in the epidemiological profile of the disease, despite the municipality still showing levels of hyperendemicity. Add a comma: Lines 447-449: “For example, studies conducted in two Brazilian regions in which leprosy is endemic, (add comma here) an assessment of health services identified that the local primary health units did not present satisfactory performance in diagnosing individuals younger than 15 years old” I do not need to review again, these are fine upon correction. Reviewer #2: The authors have solved all addressed issues and the manuscript reads much better. We believe their paper will help other researchers working with leprosy and should be published now. ********** 7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy. Reviewer #1: No Reviewer #2: Yes: MAURICIO LISBOA NOBRE |
| Formally Accepted |
|
PONE-D-20-00967R2 Trends and forecasts of leprosy for a hyperendemic city from Brazil’s northeast: Evidence from an eleven-year time-series analysis Dear Dr. Ramos: I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department. If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org. If we can help with anything else, please email us at plosone@plos.org. Thank you for submitting your work to PLOS ONE and supporting open access. Kind regards, PLOS ONE Editorial Office Staff on behalf of Dr. Eyal Oren Academic Editor PLOS ONE |
Open letter on the publication of peer review reports
PLOS recognizes the benefits of transparency in the peer review process. Therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. Reviewers remain anonymous, unless they choose to reveal their names.
We encourage other journals to join us in this initiative. We hope that our action inspires the community, including researchers, research funders, and research institutions, to recognize the benefits of published peer review reports for all parts of the research system.
Learn more at ASAPbio .